natgillin/translations-raw huggingface dataset:
Take 1 film-coated tablet of Sildenafil ratiopharm about 1 hour before sexual activity.
Uzmite 1 filmom obloženu tabletu lijeka Sildenafil ratiopharm oko sat vremena prije spolnog odnosa.
- if you have ever suffered from loss of vision due to an eye condition known as “stroke of the eye” (non-arteritic anterior ischaemic optic neuropathy, NAION).
ako ste ikada imali gubitak vida zbog stanja koje se zove "infarkt oka" (nearteritična prednja ishemijska optička neuropatija, NAION).
In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors.
U kliničkim ispitivanjima, riociguat je pokazao da pojačava hipotenzivni učinak inhibitora PDE5.
Sildenafil showed no effect on cardiac output, and did not impair blood flow through the stenosed coronary arteries.
Sildenafil nije pokazao učinak na minutni volumen srca te nije narušio protok krvi kroz sužene koronarne arterije.
In addition, initiation of sildenafil at a dose of 25 mg should be considered (see sections 4.4 and 4.5).
Nadalje, potrebno je razmotriti primjenu početne doze sildenafila od 25 mg (vidjeti dijelove 4.4 i 4.5).
The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.
Farmakokinetika sildenafila u bolesnika s teškim oštećenjem funkcije jetre nije ispitivana.
Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
Sredstva za liječenje erektilne disfunkcije, uključujući sildenafil, treba oprezno primjenjivati u bolesnika s anatomskom deformacijom penisa (kao što su angulacija, kavernozna fibroza ili Peyronijeva bolest) ili u bolesnika koji imaju stanja koja ih mogu predisponirati za prijapizam (kao što su anemija srpastih stanica, multipli mijelom ili leukemija).
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
(800 mg), inhibitor citokroma P450 i nespecifični CYP3A4 inhibitor, uzrokovao je 56%-tni porast koncentracija sildenafila u plazmi kada se primjenjivao istodobno sa sildenafilom (50 mg) u zdravih dobrovoljaca.
Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Simptomi ulkjučuju iznenadno piskanje, otežano disanje ili omaglicu, oticanje vjeđa, lica, usnica ili grla.
If you feel dizzy, or if your vision or hearing is affected after taking Sildenafil ratiopharm, do not drive or operate any tools or machines.
Ako osjetite omaglicu ili ako imate problema s vidom ili sluhom nakon uzimanja lijeka Sildenafil ratiopharm, ne smijete upravljati vozilima, odnosno rukovati alatima ili strojevima.
Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil.
Sok od grejpa slab je inhibitor CYP3A4 uključenog u metabolizam u stijenci crijeva i može izazvati umjereni porast razina sildenafila u plazmi.
In a study of the haemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija (> 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
Sildenafil ratiopharm is a treatment for adult men with erectile dysfunction, sometimes known as impotence.
Sildenafil ratiopharm je namijenjen liječenju odraslih muškaraca s erektilnom disfunkcijom, ponekad zvanom pod nazivom impotencija.
Vertigo, Tinnitus
Vrtoglavica, tinitus
Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg should be considered.
Iako u tih bolesnika nije opažena povećana incidencija štetnih događaja, kod istodobne primjene sildenafila s CYP3A4 inhibitorima potrebno je razmotriti primjenu početne doze od 25 mg.
Nasal congestion
Nazalna kongestija
In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose.
U dobrovoljaca s blagim do umjerenim poremećajem bubrega (klirens kreatinina = 30-80 ml/min), nakon uzimanja jednokratne oralne doze od 50 mg nije bilo promjena u farmakokinetici sildenafila.
Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g. aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
Bolesnici s povećanom osjetljivošću na vazodilatatore obuhvaćaju one s opstrukcijom izlaznog trakta lijevog ventrikula (npr. aortna stenoza, hipertrofična opstruktivna kardiomiopatija) ili bolesnike s rijetkim sindromom multiple sustavne atrofije koja se manifestira teškim poremećajem autonomne kontrole krvnog tlaka.
Merckle GmbH Ludwig-Merckle-Strasse 3 89143 Blaubeuren Germany
Merckle GmbH Ludwig-Merckle-Strasse 3 89143 Blaubeuren Njemačka
With the exception of ritonavir for which co-administration with sildenafil is not advised (see section 4.4), a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).
S iznimkom ritonavira, kod kojeg se istodobna primjena sa sildenafilom ne savjetuje (vidjeti dio 4.4), u bolesnika koji se istodobno liječe CYP3A4 inhibitorima potrebno je razmotriti primjenu početne doze od 25 mg (vidjeti dio 4.5).
Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of sildenafil.
Ozbiljni kardiovaskularni događaji, uključujući infarkt miokarda, nestabilnu anginu, iznenadnu srčanu smrt, ventrikularnu aritmiju, cerebrovaskularno krvarenje, tranzitornu ishemijsku ataku, hipertenziju i hipotenziju bili su prijavljeni u razdoblju nakon stavljanja lijeka u promet, kao vremenski povezani s primjenom sildenafila.
Initiation of sildenafil at a dose of 25 mg should be considered (see section 4.2).
Potrebno je razmotriti početak liječenja sildenafilom u dozi od 25 mg (vidjeti dio 4.2).
If you experience sudden decrease or loss of vision, stop taking Sildenafil ratiopharm and contact your doctor IMMEDIATELY.
Ako primijetite nagli gubitak vida, prestanite uzimati Sildenafil ratiopharm i ODMAH se obratite svom liječniku.
*Reported during post-marketing surveillance only **Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased
*Prijavljeno isključivo nakon stavljanja lijeka u promet **Vizualni poremećaj percepcije boja: kloropsija, kromatopsija,cijanopsija, eritropsija i ksantopsija ***Poremećaji suzenja: suho oko, suzni poremećaji i pojačano suzenje
The corresponding change in supine diastolic blood pressure was 5.5 mmHg.
Odgovarajuća promjena dijastoličkog krvnog tlaka u ležećem položaju iznosila je 5,5 mmHg.
If this occurs during or after intercourse: Get in a semi-sitting position and try to relax.
• Zauzmite polusjedeći položaj i pokušajte se opustiti.
- if you suffer from kidney or liver problems.
- ako imate problema s bubrezima ili jetrom.
Pooling of the following classes of antihypertensive medication, diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally-acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.
Analiza podataka sljedećih klasa antihipertenzivnih lijekova: diuretika, beta-blokatora, ACE inhibitora, antagonista angiotenzina II, antihipertenzivnih lijekova (vazodilatatora i onih sa središnjim djelovanjem), blokatora adrenergičkog neurona, blokatora kalcijevih kanala i blokatora alfaadrenoceptora, nije pokazala razlike u profilu nuspojava u bolesnika koji uzimaju sildenafil u usporedbi s liječenjem placebom.
Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8).
Slučajevi nearteritične anteriorne ishemijske optičke neuropatije, rijetkog stanja, prijavljeni su spontano i u opservacijskom ispitivanju vezano uz uzimanje sildenafila i drugih PDE5 inhibitora (vidjeti dio 4.8).
What Sildenafil ratiopharm is and what it is used for What you need to know before you take Sildenafil ratiopharm How to take Sildenafil ratiopharm Possible side effects
Što je Sildenafil ratiopharm i za što se koristi Što morate znati prije nego počnete uzimati Sildenafil ratiopharm
If you are not certain, ask your doctor or pharmacist.
Ako niste sigurni, provjerite sa svojim liječnikom ili ljekarnikom.
In order to reduce the probability of these symptoms occurring, you should start taking Sildenafil ratiopharm only when you are already well controlled on a regular daily dose of your alpha blocker.
Kako biste smanjili vjerojatnost pojave tih simptoma, Sildenafil ratiopharm smijete početi uzimati tek nakon što ste redovnom dnevnom primjenom alfablokatora postigli dobru kontrolu krvnog tlaka.
Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary.
Na temelju djelotvornosti i podnošljivosti, doza se može postupno povisiti na 50 mg sve do 100 mg prema potrebi.
A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.
Prije odluke o farmakološkom liječenju, potrebno je uzeti medicinsku anamnezu i izvršiti fizikalni pregled radi dijagnoze erektilne disfunkcije i određivanja mogućih primarnih uzroka.
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals.
Istodobna primjena sildenafila u bolesnika koji primaju terapiju alfa-blokatorom može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba.
Tachycardia, Palpitations
Tahikardija, palpitacije
(≥ 1/100 and
(≥1/100 i
Other medicines and Sildenafil ratiopharm
Drugi lijekovi i Sildenafil ratiopharm
Cases of visual defects have been reported spontaneously in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8).
Slučajevi poremećaja vida prijavljeni su spontano vezano uz uzimanje sildenafila i drugih PDE5 inhibitora (vidjeti dio 4.8).
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment.
U dobrovoljaca s blagom do umjerenom cirozom jetre (Child-Pugh A i B) klirens sildenafila bio je snižen, što je rezultiralo porastom AUC (84%) i Cmax (47%) u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja jetre.
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%),
Uzimajući u obzir sva ispitivanja, udio bolesnika koji su prijavili poboljšanje uz sildenafil bio je sljedeći: psihogena erektilna disfunkcija (84%), mješovita erektilna disfunkcija (77%), organska erektilna disfunkcija (68%), starije osobe (67%), dijabetes melitus (59%), ishemična bolest srca (69%), hipertenzija (68%), TURP (61%), radikalna prostatektomija (43%), ozljeda leđne moždine (83%), depresija (75%).
If you take more Sildenafil ratiopharm than you should Men who take too much Sildenafil ratiopharm may experience more side effects or may get severe muscle pain.
Ako uzmete više lijeka Sildenafil ratiopharm nego što ste trebali Veći broj nuspojava ili jaka bol u mišićima mogu se javiti u muškaraca koji uzmu previše tableta Sildenafil ratiopharm.
Do NOT take Sildenafil ratiopharm if you are taking medicines that contain nitrates (e.g. glycerol trinitrate) or nitric oxide donors (e.g. amyl nitrite, also called “poppers”).
NE uzimajte Sildenafil ratiopharm ako uzimate lijekove koji sadrže nitrate (primjerice glicerol trinitrat) ili donore dušikovih oksida (primjerice amil nitrit).
In order to get the maximum benefit from your medicine, it is recommended that you avoid alcohol before intake of this medicine.
Kako biste maksimalno iskoristili prednosti lijeka Sildenafil ratiopharm, preporučuje se izbjegavati alkohol prije primjene ovog lijeka.
Effects of other medicinal products on sildenafil In vitro studies
Učinci drugih lijekova na sildenafil
In order to minimise the potential of developing postural hypotension in patients receiving alpha-blocker treatment, patients should be stabilised on alpha-blocker therapy prior to initiating sildenafil treatment.
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije kod bolesnika koji dobivaju terapiju alfa-blokatorima, bolesnici moraju biti stabilizirani uz terapiju alfa blokatorima prije početka liječenja sildenafilom.
Manufacturer Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Germany
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Njemačka
What Sildenafil ratiopharm is and what it is used for
Što je Sildenafil ratiopharm i za što se koristi
Therefore, tell your doctor if you are taking any of the following medicines: - ritonavir or saquinavir (medicines for the treatment of HIV infections); - ketoconazole or itraconazole (medicines for the treatment of fungal infections); - erythromycin (an antibiotic); - cimetidine (medicine for the treatment of heartburn and peptic ulcers);
Stoga svog liječnika morate obavijestiti ako uzimate neki od sljedećih lijekova: ritonavir ili sakvinavir (lijekovi za liječenje HIV infekcija); ketokonazol ili itrakonazol (lijekovi za liječenje gljivičnih infekcija); eritromicin (antibiotik); cimetidin (lijek za liječenje žgaravice i čira na želucu); alfa-blokatore (skupina lijekova za liječenje povišenog krvnog tlaka ili povećane prostate [benigne hiperplazije prostate]).
Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).
Istovremena primjena riociguata s inhibitorima PDE5, uključujući sildenafil, je kontraindicirana (vidjeti dio 4.3).
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied.
Istodobna primjena s drugim inhibitorima PDE5 ili drugim oblicima liječenja erektilne disfunkcije Sigurnost i djelotvornost kombinacija sildenafila s drugim inhibitorima PDE5, s drugim terapijama za plućnu arterijsku hipertenziju (PAH) koje sadrže sildenafil ili s drugim oblicima liječenja erektilne disfunkcije nije ispitana.
- if you have a severe heart problem.
- ako imate teške probleme sa srcem.
Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route).
Metabolizam sildenafila uglavnom je posredovan citokromom P450 (CYP) izoformama 3A4 (glavni put) i 2C9 (sporedni put).
Prolonged erections and priapism have been reported with sildenafil in post-marketing experience.
Produžene erekcije i prijapizam prijavljeni su prilikom primjene sildenafila nakon stavljanja lijeka u promet.
GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription.
NAČIN IZDAVANJA LIJEKA Lijek se izdaje na recept.
In order to minimise the potential for developing postural hypotension, patients should be haemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment.
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije, bolesnici moraju biti hemodinamički stabilni uz liječenje alfa blokatorom prije početka liječenja sildenafilom.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
Prilikom primjene sildenafila u bolesnika koji uzimaju alfa-blokator savjetuje se oprez, jer istodobna primjena može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba (vidjeti dio 4.5).
Visual colour distortions**, Visual disturbance, Vision blurred
Vizualni poremećaj percepcije boja**, poremećaji vida, zamagljeni vid
This is most likely to occur within 4 hours post sildenafil dosing.
Do toga će najvjerojatnije doći unutar 4 sata nakon primjene sildenafila.
Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min), a 25 mg dose should be considered.
Budući da je klirens sildenafila smanjen u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min), potrebno je razmotriti primjenu doze od 25 mg.
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
Istodobna primjena s inhibitorima PDE5, uključujući sildenafil, zajedno sa stimulatorima gvanilat ciklaze, kao što je riociguat, je kontrainidicirana i može potencijalno dovesti do simptomatske hipotenzije (vidjeti dio 4.5).
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
U skladu s njegovim poznatim učincima na put dušikovog oksida/cikličkog gvanozin monofosfata (cGMP) (vidjeti dio 5.1), ustanovljeno je da sildenafil pojačava hipotenzivne učinke nitrata te je zbog toga kontraindicirana njegova istodobna primjena s donorima dušikovog oksida (kao što je amil nitrit) ili nitratima u bilo kojem obliku.
- Seizures or fits - this occurs rarely.
Napadaji ili konvulzije - javljaju se rijetko.
- if you are taking medicines that contain nitrates (e.g. glycerol trinitrate) or nitric oxide donors (e.g. amyl nitrite, also called “poppers”).
- ako uzimate lijekove koji sadrže nitrate (primjerice glicerol trinitrat) ili donore dušikovih oksida (primjerice amil nitrit).
In volunteers with severe renal impairment (creatinine clearance < 30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88% respectively compared to age-matched volunteers with no renal impairment.
U dobrovoljaca s teškim poremećajem bubrega (klirens kreatinina <30 ml/min), klirens sildenafila bio je snižen, što je rezultiralo srednjim porastom AUC i Cmax od 100%, odnosno 88% u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja bubrega.
Co-administration of sildenafil with ritonavir is not advised (see section 4.5).
Istodobna primjena s ritonavirom Istodobna primjena sildenafila s ritonavirom se ne preporučuje (vidjeti dio 4.5).
- The other ingredients are: microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate, calcium hydrogen phosphate anhydrous, talc, macrogol 6000, titanium dioxide, iron oxide red.
- Drugi sastojci su: mikrokristalična celuloza, hipromeloza, umrežena karmelozanatrij magnezijev stearat, bezvodni kalcijev hidrogenfosfat, talk, makrogol 6000, titanijev dioksid (E171), crveni željezov oksid.
- if you have a severe liver problem.
- ako imate teške probleme s jetrom.
Taking these medicines with Sildenafil ratiopharm could seriously affect your blood pressure.
Istovremena primjena tih lijekova i lijeka Sildenafil ratiopharm mogla bi ozbiljno sniziti krvni tlak.
Sildenafil ratiopharm is not indicated for use by women.
Sildenafil ratiopharm nije namijenjen za primjenu u žena.
If this medicine does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse, you should tell your doctor.
Trebate obavijestiti svog liječnika ako Vam ovaj lijek ne pomaže u postizanju erekcije ili ukoliko erekcija ne traje dovoljno dugo za dovršetak spolnog odnosa.
In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively.
U ispitivanju sa zdravim muškim dobrovoljcima, istodobna primjena antagonista endotelina, bosentana (induktor CYP3A4 [umjereni], CYP2C9 i vjerojatno CYP2C19), u stanju dinamičke ravnoteže (125 mg dva puta dnevno) sa sildenafilom u stanju dinamičke ravnoteže (80 mg tri puta dnevno), rezultirala je sa 62,6%-tnim smanjenjem AUC, odnosno 55,4%-tnim smanjenjem Cmax sildenafila.
Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3).
U skladu s njegovim poznatim učincima na put dušikovog oksida/cikličkog gvanozin monofosfata (cGMP) (vidjeti dio 5.1), pokazalo se da sildenafil pojačava hipotenzivne učinke nitrata te je zbog toga kontraindicirana njegova istodobna primjena s donorima dušikovog oksida ili nitratima u bilo kojem obliku (vidjeti dio 4.3).
Since sildenafil clearance is reduced in patients with hepatic impairment (e.g. cirrhosis), a 25 mg dose should be considered.
Budući da je klirens sildenafila smanjen u bolesnika s teškim oštećenjem funkcije jetre (npr. ciroza), potrebno je razmotriti primjenu doze od 25 mg.
EU/1/09/603/009 1 film-coated tablet EU/1/09/603/010 4 film-coated tablets EU/1/09/603/011 8 film-coated tablets EU/1/09/603/012 12 film-coated tablets EU/1/09/603/015 2 film-coated tablets EU/1/09/603/016 24 film-coated tablets EU/1/09/603/018 48 film-coated tablets
EU/1/09/603/009 1 filmom obložena tableta EU/1/09/603/010 4 filmom obložene tablete EU/1/09/603/011 8 filmom obloženih tableta EU/1/09/603/012 12 filmom obloženih tableta EU/1/09/603/015 2 filmom obložene tablete EU/1/09/603/016 24 filmom obloženih tableta EU/1/09/603/018 48 filmom obloženih tableta
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim CYP3A4 inhibitorom, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana), uočen je 182%tni porast sustavne izloženosti sildenafilu (AUC).
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
Sildenafil se uglavnom odstranjuje putem mikrosomalnih izoenzima jetre CYP3A4 (glavni put) i CYP2C9 (sporedni put).
- if you are already undergoing treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.
- ako već uzimate terapije za plućnu arterijsku hipertenziju (PAH) kje sadrže sildenafil ili neke druge inhibitore PDE5. - ako nemate erektilnu disfunkciju.